Touch Biotechnology develops rapid antigen tests for COVID-19, RSV, and influenza, enabling individuals to perform self-testing for these respiratory illnesses at home. The company also offers at-home tests for sexually transmitted infections, specifically chlamydia and gonorrhea, addressing the need for accessible and private health diagnostics.
Funding
Funding not disclosed
Founders
Product
Problem
Individuals often lack convenient and private options for testing for common respiratory illnesses and sexually transmitted infections. Traditional testing methods may require clinic visits, which can be time-consuming, costly, and may deter individuals seeking discreet testing solutions.
Solution
Touch Biotechnology provides a range of rapid antigen tests and in-vitro diagnostic tests for at-home use, enabling individuals to self-test for illnesses such as COVID-19, influenza, RSV, chlamydia, and gonorrhea. These tests offer a convenient and private alternative to traditional clinic-based testing, empowering individuals to proactively monitor their health from the comfort of their homes. The company focuses on developing effective and accessible diagnostic solutions while maintaining a commitment to social and environmental responsibility.
Target Audience
The primary target audience includes individuals seeking convenient and private at-home testing solutions for respiratory illnesses and sexually transmitted infections, as well as healthcare providers and organizations looking for rapid and accessible diagnostic tools.
Features
- Rapid antigen tests for COVID-19, Flu A/B, and RSV, available in single, dual, and triple test formats
- At-home tests for sexually transmitted infections, specifically chlamydia and gonorrhea (for females)
- Tests are TGA approved
- Tests for Urinary Tract Infection (UTI), Ferritin (Iron), and Vitamin D deficiency
- Easy-to-use kits with clear instructions for self-testing
- Results available in minutes